Remove Communication Remove Drug Development Remove Packaging
article thumbnail

The Important Role that Biopharmaceutics Plays in Accelerating Early-Phase Drug Development

Pharmaceutical Technology

As formulators, we are often able to directly impact the amount of drug absorbed through formulation optimization and improve exposure. However, the chances of improving the exposure profile of a drug that is highly cleared by formulation modification are limited. Please check your email to download the Whitepaper.

article thumbnail

Researchers find new pathways for HIV invasion of cell nucleus

Express Pharma

A study published in the journal Nature Communications has identified a new pathway that human immunodeficiency virus (HIV) uses to enter the nucleus of a healthy cell, where it can then replicate and go on to invade other cells. But how the viruses get past the protective membrane is not well understood and is the subject of much debate.

Packaging 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Researchers identify new pathway for HIV invasion of cell nucleus

Express Pharma

A study published in the journal Nature Communications has identified a new pathway that human immunodeficiency virus (HIV) uses to enter the nucleus of a healthy cell, where it can then replicate and go on to invade other cells. But how the viruses get past the protective membrane is not well understood and is the subject of much debate.

article thumbnail

Patient Engagement in Pharma – Why and How?

Viseven

The traditional model of drug development and healthcare delivery is undergoing a seismic shift, with patient engagement emerging as a critical factor in achieving better health outcomes and driving innovation. This change is further driven by major regulatory bodies emphasizing Patient-Focused Drug Development (PFDD).

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

But what are the key potential changes and how could they impact drug developers and manufacturers? He noted that within the proposals, there is likely to be a differentiation in incentives for drug development in the orphan and unmet medical need areas. Key areas of potential legislative change. Future outlook.

article thumbnail

Metaverse or Virtual Reality? What is the Difference?

Pulses

Table 1: Virtual Technology Platform: Pros and Cons Pros AR VR MR XR Metaverse Enhanced user experience/interaction √ √ Immersive and Engaging Experience √ √ Increased Collaboration and Communication √ √ √ Social interaction √ √ √ √ √ Used in training and simulation √ √ √ √ Enhanced Connectivity √ Creative Expression √ Cons Cybersickness AR VR MR XR (..)

article thumbnail

NHC Comments on PFDD: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making

Putting Patients First Blog

MACC Commissioner United States Food and Drug Administration 5 630 Fishers Lane, Rm. MACC Commissioner United States Food and Drug Administration 5 630 Fishers Lane, Rm. The NHC was a strong supporter of the inclusion of these guidances in the Prescription Drug User Fee Act (PDUFA) VI agreement. Califf M.D., Califf M.D.,